113 related articles for article (PubMed ID: 9441094)
1. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.
Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA
Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094
[TBL] [Abstract][Full Text] [Related]
2. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
[TBL] [Abstract][Full Text] [Related]
3. Development of rifapentine: the way ahead.
Mitchison DA
Int J Tuberc Lung Dis; 1998 Aug; 2(8):612-5. PubMed ID: 9712273
[No Abstract] [Full Text] [Related]
4. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728
[TBL] [Abstract][Full Text] [Related]
5. Rifapentine for the treatment of pulmonary tuberculosis.
Munsiff SS; Kambili C; Ahuja SD
Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
[TBL] [Abstract][Full Text] [Related]
6. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A; Eller MG; McKenzie KA; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
[TBL] [Abstract][Full Text] [Related]
7. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis.
Dhillon J; Dickinson JM; Guy JA; Ng TK; Mitchison DA
Tuber Lung Dis; 1992 Apr; 73(2):116-23. PubMed ID: 1643297
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
[TBL] [Abstract][Full Text] [Related]
9. Rifapentine--a long-acting rifamycin for tuberculosis.
Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
[No Abstract] [Full Text] [Related]
10. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
[TBL] [Abstract][Full Text] [Related]
12. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
[TBL] [Abstract][Full Text] [Related]
13. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
[TBL] [Abstract][Full Text] [Related]
14. Does AIDS impair the absorption of antituberculosis agents?
Taylor B; Smith PJ
Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
[TBL] [Abstract][Full Text] [Related]
15. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
[TBL] [Abstract][Full Text] [Related]
16. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
[TBL] [Abstract][Full Text] [Related]
17. Rifapentine: its role in the treatment of tuberculosis.
Temple ME; Nahata MC
Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
[TBL] [Abstract][Full Text] [Related]
18. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rifapentine in children.
Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
